A guide to Australia's big experiment with biosimilars


Until the 21st century, rheumatoid arthritis (RA) was considered a  hopeless diagnosis for many patients. Over  the past two decades, however, rheumatology has been catapulted to the cutting edge of research into immune-modulating therapies and an increasing number of biological and synthetic disease-modifying antirheumatic drugs (DMARDs) are emerging.

For a significant number of patients with RA battling pain and disability with only methotrexate, steroids and NSAIDS, the introduction of biological therapies has been transformative.

Since PBAC approval of the first one,